Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Keeping Track: Xarelto Earns CV Risk Reduction Claim In Quiet Week; Spotlight On Formal Dispute Resolution

Oct 14 2018

• By Bridget Silverman

Keeping Track Feature image

Related Content

Tired Of Winning? When It Comes To US FDA Appeals, “Denied” Can Still Mean Victory

Oct 12 2018

Keeping Track: US FDA Approves Novel Tetracyclines Nuzyra And Seysara; Hemlibra Indication Expands

Oct 07 2018

Keeping Track: Three Oncologics, A New Migraine Preventive, And First LPAD Antibiotic Clear US FDA

Oct 01 2018

Another Reorg For US FDA Drug Office: Dispute Resolution Program Moves Out

Jun 07 2018

Keeping Track: Mylan Wins First US FDA Approval For Neulasta Biosimilar, But Lands A CRL For Insulin Glargine; Genentech Nabs Broad Full Approval For Venclexta, PV Indication For Rituxan

Jun 08 2018

COMPASS Sets Course For J&J/Bayer's Xarelto In Unexplored Indications

Aug 29 2017

COMPASS Success Reinforces J&J/Bayer's Broad Labeling Strategy For Xarelto

Feb 10 2017

Related Companies

Johnson & Johnson

Spero Therapeutics, Inc.

ADMA Biologics, Inc.

Agile Therapeutics, Inc.

Bausch Health Companies Inc.

Biotest AG

Additional Topics

United States Drug Review Regulation BioPharmaceutical

More from Product Reviews

More from Pink Sheet

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window